Oss, The Netherlands and Basel, Switzerland, 9 September 2019 – The Netherlands-based biotech Citryll and CDMO Lonza announced a partnership to develop and manufacture Citryll’s tACPA therapeutic antibody CIT-013. CIT-013 targets Neutrophil Extracellular Trap (NET) biology, and could offer new treatment options for a range of diseases where NETs play a role in disease pathology including autoimmune diseases like lupus, rheumatoid arthritis, vasculitis and others. By targeting NET formation and NETs directly, CIT-013 does not broadly target inflammation or acquired immunity, but rather targets the source of autoantigens, proinflammatory as well as toxic NET components.